Ultimo aggiornamento: agosto 17, 2026
Terapia con cellule staminali per la riparazione della cartilagine articolare: Revisione dell'entità delle popolazioni cellulari utilizzate e del risultato dell'applicazione clinica di ciascuna entità
Yong-Beom Park, MD, Dottorato di ricerca, Chul-Won Ha, MD, Dottorato‖, Ji Heon Rim,..
Sfondo:
A seguito di studi preclinici di successo, terapia con cellule staminali is emerging as a candidate for the treatment of articular cartilage lesions. Because stem cell therapy for cartilage repair in humans is at an early phase, confusion and errors are found in the literature regarding use of the term stem cell therapy in this field.
Purpose:
To provide an overview of the outcomes of riparazione della cartilagine, elucidating the various cell populations used, and thus reduce confusion with regard to using the term stem cell therapy.
Progettazione dello studio:
Systematic review.
Metodi:
The authors systematically reviewed any studies on clinical application of cellule staminali mesenchimali (MSC) in human subjects. A comprehensive search was performed in MEDLINE, EMBASE, the Cochrane Library, CINAHL, Web of Science, and Scopus for human studies that evaluated articular cartilage repair with cell populations containing MSCs. These studies were classified as using bone marrow–MSC derivate, adipose tissue–derived MSCs, peripheral blood–derived MSCs, synovium-derived MSCs, and umbilical cord blood–derived MSCs according to the entity of cell population used.
Risultati:
Forty-six clinical studies were identified to focus on cartilage repair with MSCs: 20 studies with bone marrow–derived MSCs, 21 studies with adipose tissue–derived MSCs, 3 studies with peripheral blood–derived MSCs, 1 study with synovium-derived MSCs, E 1 study with umbilical cord blood–derived MSCs. All clinical studies reported that cartilage treated with MSCs showed favorable clinical outcomes in terms of clinical scores or cartilage repair evaluated by MRI. Tuttavia, most studies were limited to case reports and case series. Tra questi 46 studi clinici, 18 studies erroneously referred to adipose tissue–derived stromal vascular fractions as “adipose-derived MSCs," 2 studies referred to peripheral blood–derived progenitor cells as “peripheral blood–derived MSCs,” and 1 study referred to bone marrow aspirate concentrate as “bone marrow–derived MSCs.”
Conclusione:
Limited evidence is available regarding clinical benefit of stem cell therapy for articular cartilage repair. Because the literature contains substantial errors in describing the therapeutic cells used, researchers need to be alert and observant of proper terms, especially regarding whether the cells used were stem cells or cell populations containing a small portion of stem cells, to prevent confusion in understanding the results of a given stem cell–based therapy.
Parole chiave cartilagine, riparazione, entity, cellule staminali mesenchimali, cell concentrate, frazione vascolare stromale
Revisione scientifica del caso
Ti piacerebbe capire se i programmi clinici sono attuali, recenti sviluppi della ricerca, o potrebbero esserlo gli approcci emergenti rilevante per la tua situazione individuale?
Invia la tua domanda al nostro team scientifico. La sede centrale di NBScience nel Regno Unito coordina le richieste attraverso la rete internazionale di centri medici, scienziati, e consulenti specializzati.
- Revisione delle informazioni fornite
- Informazioni rilevanti sulla ricerca e sul programma clinico
- Una risposta chiara focalizzata sulla tua situazione
Nessun obbligo. La tua domanda verrà esaminata in modo confidenziale.
Solo informazioni didattiche e di ricerca. Questo servizio no costituiscono un parere medico, diagnosi, prescrizione, o uno personalizzato raccomandazione terapeutica.
